Abstract
Cohen MH, Olszewski Y, Branson B, et al. AIDS. 2003;17:2121–2124 The US Food and Drug Administration recently approved the OraQuick rapid human immunodeficiency virus-1 (HIV-1) antibody test (OraSure Technologies, Bethlehem, PA). The test is designed for point-of-care testing for HIV. The test is performed with a tiny amount of blood, and results are available within 20 to 30 minutes. Remarkably, this test is as sensitive and specific as the standard enzyme-linked immunosorbent assay for HIV-specific antibodies. The purpose of this study was to evaluate the differences in turnaround times between hospitals where obstetric staff members performed the rapid …
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
